Evidence map›Paper›PMID 39491534›Full record

ReviewAdvanced healthcare materials2025

Leveraging Organ-on-Chip Models to Investigate Host-Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease.

Tim Kaden, Raquel Alonso-Román, Johannes Stallhofer, Mark S Gresnigt, Bernhard Hube, Alexander S Mosig

Abstract readReview
In one paragraph

Review in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. From AI-AssistedPharmaceuticals (Basel, Switzerland) · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tim KadenDynamic42 GmbH, 07745, Jena, Germany.
Raquel Alonso-RománDepartment of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knöll-Institute, 07745, Jena, Germany.
Johannes StallhoferDepartment of Internal Medicine IV, Jena University Hospital, 07747, Jena, Germany.
Mark S GresnigtCluster of Excellence Balance of the Microverse, Friedrich Schiller University Jena, 07745, Jena, Germany.
Bernhard HubeDepartment of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knöll-Institute, 07745, Jena, Germany.
Alexander S MosigInstitute of Biochemistry II, Center for Sepsis Control and Care, Jena University Hospital, 07747, Jena, Germany.ORCID 0000-0002-5687-2444

Funding

Carl Zeiss FoundationDeutsche ForschungsgemeinschaftDFG Collaborative Research Centre CRC 316213987DFG Collaborative Research Centre (CRC)/Transregio (TRR)DFG Emmy Noether Program 434385622/GR 5617/1-1)DFG Priority Program SPP2225Exit strategies of intracellular pathogensGerman Crohn's disease/Ulcerative colitis Association (Deutsche Morbus Crohn/Colitis ulcerosa Vereinigung; DCCV e.V.)German Federal Ministry of Education and Research (BMBF) 13N15714German Federal Ministry of Education and Research (BMBF) 13N15716Germany's Excellence Strategy-EXC 2051 390713860Leibniz Association Campus InfectoOptics SAS-2015-HKI-LWCLeibniz Research Alliance INFECTIONS SAS-2021-1-FZBThüringer Aufbaubank 2021 SD0018Thüringer Aufbaubank 2023 SD0029
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is an idiopathic gastrointestinal disease with drastically increasing incidence rates. Due to its multifactorial etiology, a precise investigation of the pathogenesis is extremely difficult. Although reductionist cell culture models and more complex disease models in animals have clarified the understanding of individual disease mechanisms and contributing factors of IBD in the past, it remains challenging to bridge research and clinical practice. Conventional 2D cell culture models cannot replicate complex host-microbiota interactions and stable long-term microbial culture. Further, extrapolating data from animal models to patients remains challenging due to genetic and environmental diversity leading to differences in immune responses. Human intestine organ-on-chip (OoC) models have emerged as an alternative in vitro model approach to investigate IBD. OoC models not only recapitulate the human intestinal microenvironment more accurately than 2D cultures yet may also be advantageous for the identification of important disease-driving factors and pharmacological interventions targets due to the possibility of emulating different complexities. The predispositions and biological hallmarks of IBD focusing on host-microbiota interactions at the intestinal mucosal barrier are elucidated here. Additionally, the potential of OoCs to explore microbiota-related therapies and personalized medicine for IBD treatment is discussed.

Indexed as

Gastrointestinal MicrobiomeInflammatory Bowel DiseasesLab-On-A-Chip DevicesModels, BiologicalAnimalsHumansIntestinal Mucosahost–microbiota interactionsIBD treatmentinflammatory bowel diseaseintestine‐on‐chip

Identifiers

PMID39491534
PMCPMC12004439

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.